We are live on ! Find out more
SLNO

Soleno Therapeutics
SLNO

Delisted

SLNO was delisted on the 15th of May, 2026.

Back to rankings

0 hedge funds and large institutions have $0 invested in Soleno Therapeutics in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 220 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 225 → 0 (-225)

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

100% less capital invested

Capital invested by funds: $2.08B → $0 (-$2.08B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 220

120.6% less ownership

Funds ownership: 120.6% → 0% (-121%)

Holders
–
Holders Change
-225
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
220
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$194M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$148M
3
BlackRock
BlackRock
New York
-$125M
4
State Street
State Street
Massachusetts
-$89.8M
5
ACA
Avoro Capital Advisors
New York
-$77M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
76
Centiva Capital
New York
– -$3.39M -101,234 Closed
State of Wisconsin Investment Board
77
State of Wisconsin Investment Board
Wisconsin
– -$3.04M -90,907 Closed
Swiss National Bank
78
Swiss National Bank
Switzerland
– -$3.02M -90,300 Closed
HP
79
HealthInvest Partners
Sweden
– -$2.21M -90,184 Closed
AFM
80
Anson Funds Management
Texas
– -$2.96M -88,462 Closed
XT
81
XTX Topco
Cayman Islands
– -$2.87M -85,680 Closed
MOACM
82
Mutual of America Capital Management
New York
– -$2.77M -82,834 Closed
Rafferty Asset Management
83
Rafferty Asset Management
New York
– -$2.67M -79,622 Closed
UBS AM
84
UBS AM
Illinois
– -$2.41M -71,986 Closed
AGP
85
Artia Global Partners
Florida
– -$2.29M -68,490 Closed
SEI Investments
86
SEI Investments
Pennsylvania
– -$2.11M -62,946 Closed
EAM
87
Exome Asset Management
New York
– -$2.06M -61,673 Closed
KCA
88
KVP Capital Advisors
California
– -$2M -59,700 Closed
RhumbLine Advisers
89
RhumbLine Advisers
Massachusetts
– -$1.98M -59,285 Closed
Russell Investments Group
90
Russell Investments Group
United Kingdom
– -$1.97M -58,692 Closed
DC
91
Diametric Capital
Massachusetts
– -$1.94M -57,832 Closed
BNP Paribas Asset Management
92
BNP Paribas Asset Management
France
– -$1.94M -57,828 Closed
Citigroup
93
Citigroup
New York
– -$1.9M -56,656 Closed
SC
94
SummitTX Capital
Texas
– -$1.89M -56,585 Closed
Tudor Investment Corp
95
Tudor Investment Corp
Connecticut
– -$1.88M -56,118 Closed
Barclays
96
Barclays
United Kingdom
– -$1.82M -54,219 Closed
DT
97
DV Trading
Illinois
– -$1.81M -54,000 Closed
JP Morgan Chase
98
JP Morgan Chase
New York
– -$1.57M -51,480 Closed
EGM
99
Engineers Gate Manager
New York
– -$1.65M -49,145 Closed
MAP
100
Moody Aldrich Partners
Massachusetts
– -$1.62M -48,261 Closed
2 3
4
5 6

SLNO Hedge Fund Activity: Q2 2026 in Review

0 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2026, worth a combined $0 — down 100% from $2.08B a quarter earlier.

Sellers outnumbered buyers: 220 funds closed out of SLNO and 0 opened new positions — a net loss of 220 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Fidelity Investments, exiting entirely with an estimated $194M sold.

  • 0 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2026, down from 225 in Q1 2026.
  • Funds reported $0 of Soleno Therapeutics stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Soleno Therapeutics positions in Q2 2026 and 220 closed out, a net change of -220 holders.
  • The largest Soleno Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $194M sold.

Based on aggregated 13F filings for Q2 2026.